TGFB1 and osteogenesis imperfecta: Previous work in preclinical models has shown that increased TGF-β signaling is a pathogenetic mechanism in OI caused due to alterations in type I collagen and that inhibition of TGF-β could be of therapeutic benefit (25, 30–32).